The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

Published:2006-02-09 Issue:4 Volume:20 Page:658-663
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Khorashad J S,Anand M,Marin D,Saunders S,Al-Jabary T,Iqbal A,Margerison S,Melo J V,Goldman J M,Apperley J F,Kaeda J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404137.pdf

Reference31 articles.

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

3. Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.

4. Druker BJ, Lydon NB . Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7.

5. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005; 19: 509–512.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response;2024-04-05

2. Molecular Pathogenesis and Treatment Strategies of Chronic Myeloid Leukemia (CML);Sudan Journal of Medical Sciences;2023-12-29

3. Tackling Imatinib Resistance via Au‐nanoconjugates using A Cml Resistant Cell Line;Particle & Particle Systems Characterization;2023-08-21

4. Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response;2023-08-18

5. BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP;Cell Death & Disease;2023-04-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3